Safety of regadenoson in patients with end-stage liver disease

摘要

Background Regadenoson is a selective A_2A receptor agonist that is used for vasodilator stress myocardial perfusion imaging (MPI). Since the drug is partially metabolized by the liver, its safety in patients with end-stage liver disease (ESLD) needs to be determined.